A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer

Yumi Kim; Un-Beom Kang; Sungsoo Kim; Han-Byoel Lee; Hyeong-Gon Moon; Wonshik Han; Dong-Young Noh

추천

검색

자료유형: 학술저널

저자정보: Yumi Kim (Department of Surgery Seoul National University College of Medicine) Un-Beom Kang (Daegu Gyeongbuk Institute of Science & Technology Daegu Korea) Sungsoo Kim (Bertis Inc. Korea Seongnam Korea) Han-Byoel Lee (Department of Surgery Seoul National University College of Medicine) Hyeong-Gon Moon (Department of Surgery Seoul National University College of Medicine Seoul Korea) Wonshik Han (Department of Surgery Seoul National University College of Medicine Seoul Korea) Dong-Young Noh (Department of Surgery Seoul National University College of Medicine Seoul Korea)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.22 No.4

발행연도: 2019.1

수록면: 579 - 586 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Currently, the standard screening tool for breast cancer is screening mammography. There have been many efforts to develop a blood-based diagnostic assay for breast cancer diagnosis; however, none have been approved for clinical use at this time. The purpose of this study was to determine the accuracy of a novel blood-based proteomic test for aiding breast cancer diagnosis in a relatively large cohort of cancer patients. Methods: A blood-based test using multiple reaction monitoring (MRM) measured by mass spectrometry to quantify 3 peptides (apolipoprotein C-1, carbonic anhydrase 1, and neural cell adhesion molecule L1-like protein) present in human plasma was investigated. A total of 1,129 blood samples from 575 breast cancer patients, 454 healthy controls, and 100 patients with other malignancies were used to verify and optimize the assay. Results: The diagnostic sensitivity, specificity, and accuracy of the MRM-based proteomic assay were 71.6%, 85.3%, and 77%, respectively; the area under the receiver operating characteristic curve was 0.8323. The proteomic assay did not demonstrate diagnostic accuracy in patients with other types of malignancies including thyroid, pancreatic, lung, and colon cancers. The diagnostic performance of the proteomic assay was not associated with the timing of blood sampling before or after anesthesia. Conclusion: The data demonstrated that an MRM-based proteomic assay that measures plasma levels of three specific peptides can be a useful tool for breast cancer screening and its accuracy is cancer-type specific.

#Biomarkers #Breast neoplasms #Diagnosis #Blood proteins #Proteomics

참고문헌 (26)

참고문헌 신청

GLOBOCAN / Estimated cancer incidence, mortality and prevalence worldwide in 2012

정규원 / 2018 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 / Cancer Research and Treatment 50(2):303~316

Statistics Korea / KOrean Statistical information Service

Humphrey LL / 2002 / Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force / Ann Intern Med 137:347~360

Berrington de González A / 2011 / Estimates of the potential risk of radiation-related cancer from screening in the UK / J Med Screen 18:163~164

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

김유미

소속기관 Department of Surgery, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea.